We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 21-40 of 10,000 results
  1. Radiotherapy or systemic therapy versus combined therapy in patients with brain metastases: a propensity-score matched study

    Aim

    This study aimed to evaluate the clinical benefits of systemic therapy (ST) combined with stereotactic radiosurgery (SRS) for brain metastases...

    Yutaro Koide, Naoya Nagai, ... Takeshi Kodaira in Journal of Neuro-Oncology
    Article 16 September 2022
  2. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.

    There are several options for systemic therapy of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), including somatostatin analogues (SSA),...

    Yoshitaka Honma, Masafumi Ikeda, ... Junji Furuse in Investigational New Drugs
    Article 19 October 2023
  3. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

    Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death in the world, and hepatocellular carcinoma (HCC)...

    Jianzhong Liu, Shuai **a, ... **nnong Jiang in Discover Oncology
    Article Open access 03 July 2024
  4. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer

    Background

    The primary goal of this study was to determine overall survival (OS) in patients who underwent local treatment (metastasectomy or...

    Tiuri E. Kroese, George S. Buijs, ... Richard van Hillegersberg in Annals of Surgical Oncology
    Article Open access 05 April 2022
  5. Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy

    Immune checkpoint inhibitors (ICIs) achieve a milestone in cancer treatment. Despite the great success of ICI, ICI therapy still faces a big...

    **aoqing **ng, Qing Zhao, ... Hong Zhang in European Journal of Nuclear Medicine and Molecular Imaging
    Article Open access 09 January 2023
  6. Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?

    Purpose of Review

    As outcomes for patients with early-stage breast cancer have improved, oncologists have sought to de-escalate systemic therapy to...

    Nicole Williams, Michael Grimm, ... Maryam Lustberg in Current Breast Cancer Reports
    Article 20 December 2022
  7. Screening and treatment of latent tuberculosis in patients with solid tumors and systemic cancer therapy

    Introduction

    Tuberculosis is one of the infectious diseases with greater morbidity and mortality worldwide. Cancer causes an important...

    Miguel Borregón, David Sánchez, Elia Martínez in Clinical and Translational Oncology
    Article 21 March 2024
  8. Rare complication – skin atrophy – after systemic conservative therapy of infantile hemangioma

    Background

    Hemangiomas, also called infantile hemangiomas (IH) or hemangiomas of infancy are the most frequently seen benign vascular tumors of...

    Konstantine Chakhunashvili, Eka Kvirkvelia, ... Davit G. Chakhunashvili in BMC Pediatrics
    Article Open access 23 February 2024
  9. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis

    Background

    Systemic therapy is the standard treatment for unresectable colorectal cancer with liver metastasis (CRCLM). Transarterial...

    Yen-Cheng Chen, Ching-Wen Huang, ... Jaw-Yuan Wang in World Journal of Surgical Oncology
    Article Open access 01 December 2023
  10. The oligometastatic spectrum in the era of improved detection and modern systemic therapy

    Metastases remain the leading cause of cancer-related mortality. The oligometastasis hypothesis postulates that a spectrum of metastatic spread...

    Rohan R. Katipally, Sean P. Pitroda, ... Ralph R. Weichselbaum in Nature Reviews Clinical Oncology
    Article 12 July 2022
  11. High systemic inflammation as a novel cardiovascular risk factor and target for anti-cytokine therapy: comment regarding the triglyceride glucose index

    In the last century, there has been more than enough research that proved the association of high lipid and glucose levels with cardiovascular...

    Artemio García-Escobar, Rosa Lázaro-García, ... Raúl Moreno in The International Journal of Cardiovascular Imaging
    Article 01 April 2024
  12. Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients

    Background

    It is unknown whether the stage of the primary may influence the survival (OS) of metastatic upper tract urothelial carcinoma (mUTUC)...

    Simone Morra, Reha-Baris Incesu, ... Pierre I. Karakiewicz in World Journal of Urology
    Article 22 May 2024
  13. Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study

    Pantoprazole decreases the acidity of the tumor microenvironment by inhibiting proton pumps on the cancer cell. This possibly leads to increased...

    Vanita Noronha, Vijay Patil, ... Kumar Prabhash in Medical Oncology
    Article 21 December 2023
  14. Systemic therapy in children and adolescents with mental disorders: a systematic review and meta-analysis

    Background

    Systemic therapy (ST) is a psychotherapeutic intervention in complex human systems (both psychological and interpersonal). Cognitive...

    David Henry Seidel, Martina Markes, ... Markus von Pluto Prondzinski in BMC Psychiatry
    Article Open access 14 February 2024
  15. Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial

    Purpose

    The objective of the COLLISION RELAPSE trial is to prove or disprove superiority of neoadjuvant systemic therapy followed by repeat local...

    Madelon Dijkstra, Babette I. Kuiper, ... Martijn R. Meijerink in CardioVascular and Interventional Radiology
    Article Open access 09 November 2023
  16. Serious infections and tuberculosis in psoriasis patients receiving systemic therapy in Korea: a nationwide population-based cohort study

    Background

    Psoriasis itself, as well as its immunomodulatory drugs, may alter the immune system, increasing the risk of infections. Recent research...

    Young Ah Cho, Juhee Ahn, ... Yong Beom Choe in European Journal of Dermatology
    Article 01 May 2023
  17. Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma

    Pancreatic acinar cell carcinoma (PACC) is a rare cancer with no specific treatment. The treatment and chemotherapy for PACC are selected according...

    Makiko Urabe, Kenji Ikezawa, ... Kazuyoshi Ohkawa in Clinical Journal of Gastroenterology
    Article 14 May 2024
  18. Determining individual suitability for neoadjuvant systemic therapy in breast cancer patients through deep learning

    Background

    The survival advantage of neoadjuvant systemic therapy (NST) for breast cancer patients remains controversial, especially when considering...

    Enzhao Zhu, Linmei Zhang, ... Zisheng Ai in Clinical and Translational Oncology
    Article 28 April 2024
  19. Systemic therapy of necrobiotic xanthogranuloma: a systematic review

    Background

    Even though a plethora of systemic therapies have been proposed for necrobiotic xanthogranuloma (NXG), there is no systematic review on...

    Lisa Steinhelfer, Thomas Kühnel, ... Stephan Schreml in Orphanet Journal of Rare Diseases
    Article Open access 24 March 2022
  20. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension

    Purpose

    Although classified as group 1 pulmonary arterial hypertension (PAH), patients with systemic sclerosis-related pulmonary hypertension (SSc-PH)...

    Justin K. Lui, Ruchika A. Sangani, ... Elizabeth S. Klings in Cardiovascular Drugs and Therapy
    Article 06 January 2023
Did you find what you were looking for? Share feedback.